Services and payments associated with the medicare new technology add-on payment program.

Area of Science:

• Health Services Research
• Health Policy
• Medical Technology Assessment

Background:

• Established in 2001, the New Technology Add-On Payment (NTAP) program aims to increase Medicare beneficiary access to novel, high-cost medical technologies.
• The program requires Food and Drug Administration (FDA) authorization and demonstration of substantial clinical improvement over existing technologies.
• In Fiscal Year 2021, the FDA introduced expedited authorization pathways that permit certain technologies to bypass the substantial clinical improvement requirement.

Purpose of the Study:

• To analyze the services and associated payments for technologies approved through the NTAP program after the 2021 policy modification.
• To understand the implications of expedited FDA authorization pathways on NTAP eligibility and reimbursement.

Main Methods:

• Descriptive analysis of NTAP services and payments.
• Review of policy changes related to FDA expedited authorization and NTAP criteria.
• Examination of Medicare payment data for technologies approved post-FY2021.

Main Results:

• The study details the specific services and payment structures for NTAP-approved technologies following the policy change.
• Analysis indicates how expedited pathways affect the NTAP landscape and financial considerations for new technologies.
• Quantification of the financial impact on Medicare and beneficiaries due to altered NTAP criteria.

Conclusions:

• The 2021 policy shift has altered the criteria for NTAP, potentially broadening access to new technologies.
• Understanding these changes is crucial for healthcare providers, manufacturers, and policymakers navigating medical technology adoption.
• Further research may be needed to assess the long-term impact of expedited pathways on innovation and healthcare costs.